Medicare

What New Nursing Home Staffing Rules Would Mean For Residents And Patients

In a long-awaited and highly controversial decision, the federal Centers for Medicare and Medicaid Services (CMS) has proposed that nursing homes provide at least three hours of staff time daily for every patient or resident. Would it meaningfully improve care at nursing facilities? Not by much. The rule would require facilities to provide enough staff to deliver 33 minutes (.55 [...]

By |2023-09-05T11:37:08-04:00September 5th, 2023|nursing homes|0 Comments

Why Medicare Is Right To Negotiate Drug Prices

The Biden Administration has announced its list of the first 10 drugs that will be subject to price negotiations, a step allowed for the first time when Congress passed last year’s Inflation Reduction Act. The Pharmaceutical Manufacturers’ Association (PhRMA), the main drugmaker lobby, blasted the law. No surprise there. But its reasoning is evidence of how perverse the US health [...]

By |2023-08-30T11:36:35-04:00August 30th, 2023|Medicare|0 Comments

For The First Time, Traditional Medicare Will Pay To Support Family Caregivers

The federal agency that operates Medicare, the Centers for Medicare and Medicaid Services (CMS), is finally recognizing what families have known for, well, thousands of years:  Family members are the bedrock of the system of care for frail older adults and younger people with disabilities. And the agency is taking some important steps to help them. Some proposals will provide [...]

By |2023-08-23T11:35:50-04:00August 23rd, 2023|family caregivers, Medicare, Uncategorized|0 Comments

Should People With No Symptoms Get A Diagnosis of Alzheimer’s Disease?

The National Institute on Aging and the Alzheimer’s Association have proposed revised clinical guidelines that would designate seven major stages of the brain disease. The first two would be for people who have no symptoms but may be at higher risk for Alzheimer’s. These technical guidelines, which would update a 2018 version, could have enormous, and conflicting, implications for drug [...]

By |2023-08-08T10:47:15-04:00August 8th, 2023|dementia|0 Comments

FDA Has Approved The Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai and Biogen. Here is what you need to know: What does it do? In a formal phase 3 trial, Leqembi was shown to slow the progression of memory loss and cognitive impairment in patients with early-stage Alzheimer’s disease by [...]

By |2023-07-06T17:25:34-04:00July 6th, 2023|dementia, Uncategorized|0 Comments

Why Are Care Delivery Models For People With Dementia Developing So Slowly?

Enormous attention is being given to controversial drugs aimed at slowing the progression of early-stage Alzheimer’s disease. Yet, a very different set of clinical innovations holds the promise of helping far more people living with dementia and their families in more immediate—and perhaps more effective—ways. These care delivery models are aimed at breaking down the often-impenetrable barriers between health care [...]

By |2023-06-27T10:36:59-04:00June 27th, 2023|dementia, Uncategorized|0 Comments

The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules

The drug industry and its supporters are blasting the Centers for Medicare and Medicaid Services (CMS) for proposing to limit Medicare payments for the new anti-Alzheimer’s drug lecanemab to patients who participate in a trial or a special registry aimed at tracking their experience with the drug. CMS says the record-keeping will help provide important, real-world information about the benefits [...]

By |2023-06-14T12:12:06-04:00June 14th, 2023|dementia|0 Comments

The War Over Whether Medicare Should Pay For New Anti-Alzheimer’s Drugs

The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And it is publicly pressing Medicare to pay for the widespread use of the monoclonal antibodies FDA already has [...]

By |2023-05-17T15:27:50-04:00May 17th, 2023|dementia|0 Comments

As The Covid Health Emergency Ends, Medicare Will Stop Paying for Many Skilled Nursing Stays

As the Covid-19 public health emergency ends, many older adults who need a post-hospital stay in a skilled nursing facility (SNF) will be in for an unpleasant surprise: Traditional Medicare may not pay. The change, one among dozens that affect older adults, restores rules from before the pandemic. But they are complicated and will shock many patients and their families, [...]

By |2023-05-11T10:22:26-04:00May 11th, 2023|nursing homes|0 Comments

Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi

Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai. One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests that people with a condition that affects as many as half of those with Alzheimer’s Disease may be [...]

By |2023-04-25T10:22:43-04:00April 25th, 2023|dementia|0 Comments